Ascendis Pharma (ASND) said Monday it granted Novo Nordisk (NVO) an exclusive global license to develop and commercialize TransCon technology-based products in metabolic diseases and a product-by-product exclusive license in cardiovascular diseases.
Under the terms of the deal, Novo Nordisk will also receive exclusive rights to expand any resulting metabolic disease products into other therapeutic areas.
The lead program in the partnership will be a once-monthly GLP-1 receptor agonist product candidate that will initially target obesity and type-2 diabetes, Ascendis said. In exchange for the license, the company will be eligible to receive total payments of up to $285 million for the lead program. It will also be eligible to receive sales-based milestone payments and tiered royalties on global net sales.
For each additional metabolic or cardiovascular disease product candidate, the company will be eligible to receive up to $77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.
The companies expect to close the transaction before the end of 2024, Ascendis said.
Price: 124.61, Change: -0.67, Percent Change: -0.53
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。